Jill G Zwicker1, Steven P Miller2, Ruth E Grunau3, Vann Chau4, Rollin Brant5, Colin Studholme6, Mengyuan Liu6, Anne Synnes3, Kenneth J Poskitt7, Mikaela L Stiver4, Emily W Y Tam4. 1. Department of Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, Canada; Department of Pediatrics, University of British Columbia, Vancouver, Canada; Child and Family Research Institute, Vancouver, Canada. Electronic address: jill.zwicker@ubc.ca. 2. Department of Pediatrics, University of British Columbia, Vancouver, Canada; Child and Family Research Institute, Vancouver, Canada; Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada. 3. Department of Pediatrics, University of British Columbia, Vancouver, Canada; Child and Family Research Institute, Vancouver, Canada; British Columbia Women's Hospital, Vancouver, Canada. 4. Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada. 5. Child and Family Research Institute, Vancouver, Canada; Department of Statistics, University of British Columbia, Vancouver, Canada. 6. Departments of Bioengineering and Pediatrics, University of Washington, Seattle, WA. 7. Child and Family Research Institute, Vancouver, Canada; Department of Radiology, University of British Columbia, Vancouver, Canada.
Abstract
OBJECTIVE: To examine the relationship between morphine exposure and growth of the cerebellum and cerebrum in very preterm neonates from early in life to term-equivalent age, as well as to examine morphine exposure and brain volumes in relation to neurodevelopmental outcomes at 18 months corrected age (CA). STUDY DESIGN: A prospective cohort of 136 very preterm neonates (24-32 weeks gestational age) was serially scanned with magnetic resonance imaging near birth and at term-equivalent age for volumetric measurements of the cerebellum and cerebrum. Motor outcomes were assessed with the Peabody Developmental Motor Scales, Second Edition and cognitive outcomes with the Bayley Scales of Infant and Toddler Development, Third Edition at 18 months CA. Generalized least squares models and linear regression models were used to assess relationships between morphine exposure, brain volumes, and neurodevelopmental outcomes. RESULTS: A 10-fold increase in morphine exposure was associated with a 5.5% decrease in cerebellar volume, after adjustment for multiple clinical confounders and total brain volume (P = .04). When infants exposed to glucocorticoids were excluded, the association of morphine was more pronounced, with an 8.1% decrease in cerebellar volume. Morphine exposure was not associated with cerebral volume (P = .30). Greater morphine exposure also predicted poorer motor (P < .001) and cognitive outcomes (P = .006) at 18 months CA, an association mediated, in part, by slower brain growth. CONCLUSIONS: Morphine exposure in very preterm neonates is independently associated with impaired cerebellar growth in the neonatal period and poorer neurodevelopmental outcomes in early childhood. Alternatives to better manage pain in preterm neonates that optimize brain development and functional outcomes are urgently needed.
OBJECTIVE: To examine the relationship between morphine exposure and growth of the cerebellum and cerebrum in very preterm neonates from early in life to term-equivalent age, as well as to examine morphine exposure and brain volumes in relation to neurodevelopmental outcomes at 18 months corrected age (CA). STUDY DESIGN: A prospective cohort of 136 very preterm neonates (24-32 weeks gestational age) was serially scanned with magnetic resonance imaging near birth and at term-equivalent age for volumetric measurements of the cerebellum and cerebrum. Motor outcomes were assessed with the Peabody Developmental Motor Scales, Second Edition and cognitive outcomes with the Bayley Scales of Infant and Toddler Development, Third Edition at 18 months CA. Generalized least squares models and linear regression models were used to assess relationships between morphine exposure, brain volumes, and neurodevelopmental outcomes. RESULTS: A 10-fold increase in morphine exposure was associated with a 5.5% decrease in cerebellar volume, after adjustment for multiple clinical confounders and total brain volume (P = .04). When infants exposed to glucocorticoids were excluded, the association of morphine was more pronounced, with an 8.1% decrease in cerebellar volume. Morphine exposure was not associated with cerebral volume (P = .30). Greater morphine exposure also predicted poorer motor (P < .001) and cognitive outcomes (P = .006) at 18 months CA, an association mediated, in part, by slower brain growth. CONCLUSIONS:Morphine exposure in very preterm neonates is independently associated with impaired cerebellar growth in the neonatal period and poorer neurodevelopmental outcomes in early childhood. Alternatives to better manage pain in preterm neonates that optimize brain development and functional outcomes are urgently needed.
Authors: Susanne Brummelte; Ruth E Grunau; Vann Chau; Kenneth J Poskitt; Rollin Brant; Jillian Vinall; Ayala Gover; Anne R Synnes; Steven P Miller Journal: Ann Neurol Date: 2012-02-28 Impact factor: 10.422
Authors: Joke de Graaf; Richard A van Lingen; Abraham J Valkenburg; Nynke Weisglas-Kuperus; Liesbeth Groot Jebbink; Barbara Wijnberg-Williams; Kanwaljeet J S Anand; Dick Tibboel; Monique van Dijk Journal: Pain Date: 2012-12-20 Impact factor: 6.961
Authors: K J S Anand; R Whit Hall; Nirmala Desai; Barbara Shephard; Lena L Bergqvist; Thomas E Young; Elaine M Boyle; Ricardo Carbajal; Vinod K Bhutani; Mary Beth Moore; Shari S Kronsberg; Bruce A Barton Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Rakesh Rao; Jackie S Sampers; Shari S Kronsberg; Josephine V Brown; Nirmala S Desai; K J S Anand Journal: Am J Perinatol Date: 2007-09-28 Impact factor: 1.862
Authors: Ruth E Grunau; Michael F Whitfield; Julianne Petrie-Thomas; Anne R Synnes; Ivan L Cepeda; Adi Keidar; Marilyn Rogers; Margot Mackay; Philippa Hubber-Richard; Debra Johannesen Journal: Pain Date: 2009-05 Impact factor: 6.961
Authors: Manon Ranger; Cecil M Y Chau; Amanmeet Garg; Todd S Woodward; Mirza Faisal Beg; Bruce Bjornson; Kenneth Poskitt; Kevin Fitzpatrick; Anne R Synnes; Steven P Miller; Ruth E Grunau Journal: PLoS One Date: 2013-10-18 Impact factor: 3.240
Authors: Chandler Rebecca Lee Mongerson; Russell William Jennings; David Zurakowski; Dusica Bajic Journal: Int J Dev Neurosci Date: 2019-09-26 Impact factor: 2.457
Authors: Lillian G Matthews; T E Inder; L Pascoe; K Kapur; K J Lee; B B Monson; L W Doyle; D K Thompson; P J Anderson Journal: Cerebellum Date: 2018-10 Impact factor: 3.847
Authors: Emma G Duerden; Ruth E Grunau; Ting Guo; Justin Foong; Alexander Pearson; Stephanie Au-Young; Raphael Lavoie; M Mallar Chakravarty; Vann Chau; Anne Synnes; Steven P Miller Journal: J Neurosci Date: 2017-12-18 Impact factor: 6.167
Authors: Lillian G Matthews; Brian H Walsh; Clare Knutsen; Jeffrey J Neil; Christopher D Smyser; Cynthia E Rogers; Terrie E Inder Journal: Pediatr Res Date: 2018-02-07 Impact factor: 3.756
Authors: Elizabeth Allocco; Marjorie Melker; Florencia Rojas-Miguez; Caitlin Bradley; Kristen A Hahn; Elisha M Wachman Journal: Adv Neonatal Care Date: 2016-10 Impact factor: 1.968